Neurotoxicity of bortezomib therapy in m
β
Ashraf Badros; Olga Goloubeva; Jay S. Dalal; Ilyas Can; Jennifer Thompson; Aaron
π
Article
π
2007
π
John Wiley and Sons
π
English
β 95 KB
π 1 views
## Abstract ## BACKGROUND. Bortezomib is active in heavily pretreated multiple myeloma patients; the doseβlimiting toxicity is peripheral neuropathy (PN). ## METHODS. The authors retrospectively reviewed the incidence, severity, and risk factors for PN in 78 patients who received bortezomib. The